LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced the initiation of a Phase II clinical trial to assess the effect on pulmonary function, safety, tolerability and pharmacokinetic profile of zileuton injection, the Company’s investigational compound for adjunctive use with current therapies for acute exacerbations of asthma.
